Sphingosine 1-phosphate receptor agonists: a patent review (2010 – 2012)

2013 ◽  
Vol 23 (7) ◽  
pp. 817-841 ◽  
Author(s):  
Edward Roberts ◽  
Miguel Guerrero ◽  
Mariangela Urbano ◽  
Hugh Rosen
2012 ◽  
Vol 22 (8) ◽  
pp. 2794-2797 ◽  
Author(s):  
Qinghua Meng ◽  
Baowei Zhao ◽  
Qiongfeng Xu ◽  
Xuesong Xu ◽  
Guanghui Deng ◽  
...  

2003 ◽  
Vol 13 (20) ◽  
pp. 3401-3404 ◽  
Author(s):  
Jeremy J. Clemens ◽  
Michael D. Davis ◽  
Kevin R. Lynch ◽  
Timothy L. Macdonald

ChemInform ◽  
2004 ◽  
Vol 35 (3) ◽  
Author(s):  
Jeremy J. Clemens ◽  
Michael D. Davis ◽  
Kevin R. Lynch ◽  
Timothy L. Macdonald

2005 ◽  
Vol 15 (15) ◽  
pp. 3568-3572 ◽  
Author(s):  
Jeremy J. Clemens ◽  
Michael D. Davis ◽  
Kevin R. Lynch ◽  
Timothy L. Macdonald

2013 ◽  
Vol 24 (1) ◽  
pp. 29-46 ◽  
Author(s):  
Yang Yang ◽  
Hao Li ◽  
Richard Ward ◽  
Linghuan Gao ◽  
Ji-Fu Wei ◽  
...  

2019 ◽  
Vol 26 (2) ◽  
pp. 216-228 ◽  
Author(s):  
Thangaraj Karuppuchamy ◽  
Christopher J Tyler ◽  
Luke R Lundborg ◽  
Tamara Pérez-Jeldres ◽  
Abigail K Kimball ◽  
...  

Sphingosine-1-phosphate (S1P) receptor agonists are a promising therapeutic alternative to anti-integrin antibodies in inflammatory bowel disease. Here, we report that modulation of tissue S1P levels via inhibition of the S1P lyase might be an effective alternative, acting by interference with thymocyte maturation.


Sign in / Sign up

Export Citation Format

Share Document